News
Public · Published
Guggenheim maintains IDEAYA Biosciences at Buy, lowers price target to $52 from $57
Guggenheim kept its Buy rating on IDEAYA Biosciences but cut its price target to $52 from $57, an 8.8% decrease. The new target implies 66.0% upside from the Nov. 3 closing price of $31.33. Recent analyst targets listed range from $48 to $63.
Published:
Updated:
What happened
Guggenheim kept its Buy rating on IDEAYA Biosciences but cut its price target to $52 from $57, an 8.8% decrease. The new target implies 66.0% upside from the Nov. 3 closing price of $31.33. Recent analyst targets listed range from $48 to $63.
Confirmed
Global impact / market context
The lower target signals a less optimistic valuation from Guggenheim, even though its Buy rating is unchanged. Analyst targets can shape investor expectations and positioning, but the article gives no new company operating results or explanation for the cut.
Analyst inference
The supplied roundup shows differing views: recent targets range from $48 to $63, while Guggenheim's revised target is $52. These are analysts’ estimates, not guaranteed prices, and the article does not describe a share-price response to the change.
Confirmed
What to watch
- Watch for IDEAYA’s next company update, since operating results or development news could help explain whether Guggenheim’s lower valuation reflects changing expectations. Analyst inference
- Check whether Guggenheim or other analysts publish further rating or target changes; the listed recent targets span $48 to $63. Analyst inference
- Compare future share prices with the $31.33 Nov. 3 close and analyst targets, while remembering those targets are estimates rather than promises. Analyst inference
Evidence
- Original source link unavailable